Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

Equities research analysts at Zacks Research issued their Q1 2027 earnings per share estimates for Allogene Therapeutics in a ...

Almost two years after being diagnosed with Stage 3, Group 3 Rhabdomyosarcoma, Philipsburg’s C.J. Coudriet is giving back to ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...

Coldwater Creek snakes through Wedgewood, hugging the subdivision’s contours on its meandering 14-mile journey northeast from ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

Leukemia and other cancers of the blood are more difficult to target than cancers that produce localized tumors because the cancerous cells circulate throughout the body and can't be surgically ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses ...

Even in the case of uncomplicated infections, the body prepares itself early on for the possibility of a more severe course.

3, 2025 — Drug-carrying DNA aptamers can deliver a one-two punch to leukemia ... stem cells that seed cancer relapses, researchers report. The aptamers -- short ... New CAR-T Cell Therapy ...